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Abstract
Background: Surgery is the primary treatment of skeletal metastases from renal cell carcinoma, because radiation and 
chemotherapy frequently are not effecting the survival. We therefore explored factors potentially affecting the survival 
of patients after surgical treatment.
Methods: We retrospectively reviewed 101 patients operatively treated for skeletal metastases of renal cell carcinoma 
between 1980 and 2005. Overall survival was calculated using the Kaplan-Meier method. The effects of different 
variables were evaluated using a log-rank test.
Results: 27 patients had a solitary bone metastasis, 20 patients multiple bone metastases and 54 patients had 
concomitant visceral metastases. The overall survival was 58% at 1 year, 37% at 2 years and 12% at 5 years. Patients with 
solitary bone metastases had a better survival (p < 0.001) compared to patients with multiple metastases. Age younger 
than 65 years (p = 0.036), absence of pathologic fractures (p < 0.001) and tumor-free resection margins (p = 0.028) 
predicted higher survival. Gender, location of metastases, time between diagnosis of renal cell carcinoma and 
treatment of metastatic disease, incidence of local recurrence, radiation and chemotherapy did not influence survival.
Conclusions: The data suggest that patients with a solitary metastasis or a limited number of resectable metastases 
are candidates for wide resections. As radiation and chemotherapy are ineffective in most patients, surgery is a better 
option to achieve local tumor control and increase the survival.
Background
Renal cell cancer (RCC) is among the 10 most common
cancers in both men and women. It comprises 2-3% of all
malignancies [1]. The incidence of RCC in the United
States has been increasing at a rate of approximately 3%
per year [2]. Approximately one third of patients with
newly diagnosed RCC have metastatic disease at the ini-
tial presentation [3]. The most common site for metasta-
sis from RCC is the lung (50% of patients), followed by
the skeleton (20% to 50% of patients) [4,5].
Approximately 50% of patients presenting with metas-
tases die within the first year and only 10% survive more
than 5 years [6]. Compared to other types of carcinoma
frequently affecting bone the prognosis of RCC is better
than for lung cancer, but not as good as for breast or pros-
tate cancer [2]. The main reason for the poor prognosis is
the poor response of RCC metastases to radiation and
chemotherapeutic regimens [7].
P a t i e n t s  w i t h  s o l i t a r y  b o n e  m e t a s t a s i s  f r o m  R C C
reportedly have the best prognosis, with a 5 year-survival
rate between 35% and 60% [8]. Owing to the longer sur-
vival of patients with solitary bone metastasis, a number
of authors recommend a surgical approach with curative
intent and implant stabilization to prevent local disease
progression [7-11].
The aim of this study was to identify clinical, pathologi-
cal and surgical factors that are associated with better
survival of patients after surgical treatment of skeletal
metastases from RCC.
Methods
We retrospectively reviewed a consecutive series of 101
patients surgically treated for osseous metastases from
RCC between 1980 and 2005. Clinical data for these
patients were obtained through hospital records and the
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patient database system. The minimum clinical follow up
was 24 months or until death (range 1-244 months). Due
to the clear retrospective nature of the study an approval
by the ethic committee was not necessary at our univer-
sity. Perioperative variables collected were age and gender
of the patient, type of surgery, complications, time period
after first diagnosis of RCC and after onset of symptoms,
metastatic pattern, location of metastases, incidence of
pathologic fracture and local recurrence and time of sur-
vival.
Preoperative investigations included conventional
radiographs, CT scan or MRI to evaluate the size and site
of the tumor. If the diagnosis of metastasis was in ques-
tion, a preoperative needle biopsy was obtained to con-
firm the histological diagnosis. CT scans of the chest,
abdomen and pelvis were performed to evaluate visceral
metastases. In all cases the diagnosis of metastatic RCC
was confirmed by the intraoperative obtained histological
examination.
The surgical treatment for bone metastases varied in
each patient. Factors influencing the choice of surgery
included age, disease status, symptoms, morbidity of the
patient, the location and extend of bone disease, exis-
tence of extraosseous metastases and the patient's wishes.
Until the year 1997 we pursued a comparatively palliative
treatment concept with limited surgery. After that time as
a result of reports in the literature, we changed to a surgi-
cal approach with more curative intent, especially for
patients with localized metastatic disease [9,11-14]. This
included an interdisciplinary surgical regimen for
patients with a limited amount of additional visceral
metastases. This subpopulation was also analysed.
Survival was analyzed with respect to location and dis-
semination of metastases, age, interval after diagnosis of
RCC, existence of pathologic fractures, local recurrences,
margin of the resection and the use of chemotherapy and
radiation. Results of the palliative surgical treatment used
until 1997 were compared with those surgical approach
with more curative intent used after 1997.
Statistical analyses were performed using MedCalc v
10.3.1 (MedCalc Software, Mariakerke, Belgium). Inci-
dences of local recurrence in respect to different treat-
ment regimes were analysed using the McNemar test.
The survival distribution for overall survival was esti-
mated using the Kaplan-Meier method [15]. Correlations
of survival were calculated using the log-rank test with p
< 0.05 defined as significant.
Results
A total of 116 surgical procedures were performed in 101
patients. The demographic data of the patients are shown
in Table 1. 26.7% had solitary bone metastases, 19.8% had
multiple bone metastases and 53.5% had concomitant
visceral metastases at the time of presentation. In 33% of
patients osseous metastases were detected at the same
time as the RCC was diagnosed.
According to the Enneking classification [16] 8 (6.9%)
radical resections, 18 (15.5%) wide excisions, 64 (55.2%)
marginal excisions and 26 (22.4%) intracapsular excisions
were performed. The types of surgery performed are
shown in table 2. Four patients (3.4%) died within a post-
operative period of 30 days. The complication rate after
surgery was 9.5% (11/116). The type and quantity of com-
plications is shown in table 3. We included those compli-
cations that either prolonged the hospitalisation or made
a second surgical intervention necessary. For 78 patients
(77.2%) the treatment included radiation, 19 patients
before and 59 patients after the surgical procedure. Che-
motherapy was used in 36 cases (35.6%) (19 patients
(18.8%) preoperatively and 17 patients (16.8%) postopera-
tively).
Table 1: Demographics
Gender
Male 71
Female 30
Age at time of surgery
Median 64.5 years
Interquartile range 57.3-72.1 years
Time between diagnosis of RCC and 
osseous metastasis
Median 9.7 months
Interquartile range 1.0-49.0 months
Sites 116
Spine 29
Upper extremity 40
Clavicle/scapula 6
Humerus 28
Forearm 5
Lower extremity 47
Pelvis 15
Femur 29
Tibia 3
Foot 1
Symptoms at time of presentation
Pain 83%
Pathologic fracture 36%
Neurological deficit 11%
Tumor 20%
Duration of symptoms before 
presentation
Median 2.0 months
Interquartile range 1.0-4.3 monthsFottner et al. BMC Musculoskeletal Disorders 2010, 11:145
http://www.biomedcentral.com/1471-2474/11/145
Page 3 of 6
17 patients (16.8%) developed a local recurrence. 11 of
these 17 cases (64.7%) were treated by reresection of the
tumor. Two patients with local recurrence received radia-
tion therapy for pain reduction, and 4 patients were not
treated owing to tumor progression. Radiation did signif-
icantly (p = 0.377) not affect the incidence of local recur-
rence. A local recurrence occurred in 10.5% (2/19) of
patients who received radiation treatment preoperatively,
in 18.6% (11/59) of patients who received radiation treat-
ment postoperatively, and in 17.4% (4/23) of patients who
did not receive radiation treatment. Local recurrence was
significantly (p < 0.001) less frequent in patients with neg-
ative resection margins 4.7% (1/21), when compared to
those with tumor-infiltrated margins 20% (16/80).
The overall survival rates of all 101 patients were 58.4%
at 1 year, 36.6% at 2 years, 23.8% at 3 years and 11.9% at 5
years. The mean survival time was 26.9 months, median
survival 15.8 months (interquartile range: 6.8 - 34.6
months). The difference in survival between patients with
solitary bone metastases, multiple bone metastases, and
additional visceral metastases was statistically significant
(p < 0.001) (Figure 1). Patients with a solitary bone metas-
tasis had a significantly better (p = 0.002) survival than
patients with multiple bone metastases.
The histologic resection margin also affected overall
survival. Patients with a tumor-free resection margin had
a significant better (p = 0.028) survival (Figure 2). Patients
diagnosed as being free of disease any time after the oper-
ation had the best overall survival (p < 0.001) (Figure 3).
16 of the these 23 patients had additional visceral metas-
tases resected in an interdisciplinary regimen to achieve
the status of "free of disease". 13 resections were per-
formed before and 3 resections after the surgical inter-
vention of the bone metastasis. This subpopulation had
also a better (p < 0.001) survival.
Patients with a pathologic fracture had a significantly
shorter (p < 0.001) survival compared with patients with-
out pathologic fracture (Figure 4).
Of the variables analyzed: gender, time after diagnosis
of RCC, localization of the metastases, incidence of local
recurrence and the use of chemotherapy or radiation
before or after surgery did not have a significant effect on
the overall survival (Table 4). The alteration of the surgi-
cal approach in 1997 to a more curative treatment con-
cept also had no influence (p = 0.67) on the overall
survival. Only patients with solitary bone metastases had
a better (p = 0.048) survival with the more curative
approach.
Discussion
We were trying to identify factors that are associated with
better survival of patients after surgical treatment of skel-
etal metastases from RCC. Patients with osseous metas-
tases of RCC have an unfavorable prognosis. In some
studies, more than 50% of patients die within the first
year [7,9,10,17,18]. The survival rate for our patients was
with 58.4% at 1 year and 11.9% at 5 years slightly better.
However, in some studies patients had a better survival
Figure 1 A Kaplan-Meier survival curve of patients based on the 
metastatic pattern shows that patients with solitary bone metas-
tases had a better survival (p < 0.001) than patients with multiple 
bone metastases or additional visceral metastases.
Table 2: Types of Surgery
Radical resection/amputation 8
Wide excision 18
Resection arthroplasty 14
Structural graft 4
Marginal excision 64
Resection arthroplasty 16
Plate fixation 33
Intramedullary nail 4
Without internal fixation 11
Intracapsular excision 26
Resection arthroplasty 7
Plate fixation 6
Intramedullary nail 5
Without internal fixation 8
Table 3: Complications
Wound healing disorder 2
Nerve palsy 3
Haematoma (revised) 1
Infection of endoprosthesis 1
Dislocation of endoprosthesis 1
Pneumonia 2
Fracture 1Fottner et al. BMC Musculoskeletal Disorders 2010, 11:145
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rate [8,12,19], but Althausen et al. 1997 [12] and Tobisu et
al. 1989 [19] studied small patient sample, and Fuchs et al.
2005 [8] investigated only patients with solitary bone
metastases.
Comparable to other studies, the Kaplan-Meier survival
rate curves (Figure 1, 2, 3 and 4) contain two main fea-
tures: survival decreases steeply in the first year, and the
curve diminishes after a period of proximally 24 months.
The first, and most important, decision of a surgeon
dealing with patients who have metastases from RCC is
to select the appropriate treatment concept with respect
to the extent of the metastatic disease and prognosis of
the patient. For patients with the potential of becoming a
long-term survivor, an aggressive surgical resection
should be considered [7,10,11].
The metastatic pattern with solitary bone metastases
has been identified as having the strongest association
with survival [7-11,20,21]. We came to the same conclu-
sion; patients with solitary bone metastases had a better
survival rate than patients with multiple bone metastases
or visceral involvement.
We found patients younger than 65 years and patients
without a pathologic fracture at the time of surgery have a
better prognosis. Two other studies [8,17] came to the
same conclusions concerning younger patients. But most
studies examining patients with metastases from RCC
have reported no correlation concerning the age with sur-
vival [7,9,10,12,20,21]. The influence of pathologic frac-
tures on survival was analyzed in a few studies. Although
some studies [20,22-24] verified that patients with a
pathologic fracture had an unfavorable survival, one
study could not support the importance of pathologic
fractures [12].
Factors that did not influence survival in our study were
gender, local recurrence, radiation, chemotherapy and
location of metastases. Although only one study associ-
ated male gender with prolonged survival [8], gender was
not important in other studies [4,7,9,10,12,17,20]. The
influence of local recurrence on survival was analyzed in
only one study [20]. This study confirms our suggests that
a local recurrence of the tumor does not decrease the
prognosis.
A controversial factor is the influence of the location of
metastases on the prognosis. Although two studies [7,12]
show there is a difference in the survival rate between
metastases of the axial compared with the appendicular
skeleton, our findings, and two other studies [4,7] could
not detect an influence of the location.
Figure 2 A Kaplan-Meier survival curve of patients based on the 
surgical margin according to the Enneking classification 
[16]shows that patients with a tumor-free resection margin have 
a better survival rat (p = 0.028) than patients with a tumor-infil-
trated resection margin.
Figure 3 A Kaplan-Meier survival curve of patients stratified on 
the basis of being diagnosed as "free of disease" or not shows 
that patients with the diagnosis "free of disease" at any time after 
the operation had a better survival (p < 0.001).
Figure 4 A Kaplan-Meier survival curve of patients based on 
whether a pathologic fracture was present before the operation 
or not shows that presence of a pathologic fracture decreases the 
prognosis of the patient (p < 0.001).Fottner et al. BMC Musculoskeletal Disorders 2010, 11:145
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For patients with multiple metastases and a limited sur-
vival time, surgery remains the preferred therapy because
RCC often is resistant to chemotherapy and radiation
therapy [8,10,12,24-27]. Even though radiation of osseous
metastases can be useful for pain control and prevention
of fractures [28], surgery is more effective in restoring
function and preventing local tumor progression [11,24].
The analysis of the 17 cases of local recurrence in our
patients did not show a preventive effect of radiation for
local tumor progression. On the contrary, the incidence
of local recurrence was less frequent for surgical proce-
dures with tumor-free margin.
As bone metastasis stands for an advanced stage of dis-
ease, it was considered a secondary goal to achieve cure
of disease by radical resection of the tumor. However,
favorable survival rates after successful radical resection
of bony metastases justify a surgical approach with more
curative intent [7-10,20,29,30]. The therapeutic concept
at our institution was changed in 1997 to a more curative
approach. We believe this was the right decision, as we
observed a substantial improvement in survival with the
new therapeutic concept for patients with solitary metas-
tasis.
Regarding the operative procedures, our data confirm
other studies that a resection with a tumor-free margin
increases the survival rate [7,8,12,24]. We believe one
should aim for the widest resection of metastases as tech-
nically possible. Even patients with a combination of rese-
Table 4: Analysis of overall survival
Variable/Subgroup Number of
patients
Overall survival at 1 year Overall survival at 5 years p-Value
Metastatic pattern < 0.001
Solitary bone 27 0.78 0.44
Multiple bone 20 0.69 0.10
Bone and visceral 54 0.43 0.06
Local recurrence 0.060
yes 17 0.82 0.14
no 84 0.52 0.12
Gender 0.765
Female 30 0.52 0.19
Male 71 0.59 0.16
Age 0.036
< 65 years 53 0.62 0.24
> 65 years 48 0.52 0.07
Time of operation 0.670
After 1997 49 0.58 0.18
Before 1997 52 0.56 0.15
Time after diagnosis of RCC 0.081
< 2 years 64 0.48 0.14
> 2 years 37 0.72 0.19
Localisation 0.817
Appendicular 58 0.56 0.15
Axis 43 0.58 0.15
Adjuvant chemotherapy 0.370
None 65 0.55 0.13
Pre-operative 19 0.56 0.14
Post-operative 17 0.65 0.30
Radiation 0.861
None 23 0.61 0.16
Pre-operative 19 0.62 0.17
Post-operative 59 0.54 0.16Fottner et al. BMC Musculoskeletal Disorders 2010, 11:145
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cable osseous and visceral metastases are candidates for
an interdisciplinary curative surgical regimen because the
status of "free of disease" gave the patients in our study
the best chance to become long-term survivors (> 40%
survival rate after 5 years).
Conclusions
Similar to other studies we found that patients with soli-
tary metastases without pathologic fracture have the best
prognosis for long-term survival. More controversial pre-
dictors are age, gender, local recurrence, the interval after
diagnosis of RCC and the location of the metastases. For
patients with mid-term to long-term prognosis, surgeons
should try to achieve tumor-free margins to enhance the
survival rate and achieve local tumor control. This also
applies to patients with a limited amount of resectable
osseous and visceral metastases. As radiation and chemo-
therapy have little effect on survival, even patients with an
unfavorable prognosis should be considered for surgery.
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